Thanks, Ryan. It's great to be with you all this morning. I want to start by echoing what Ryan said in that we're all extremely pleased by our third quarter results. Our corporate strategy is paying dividends and delivering impressive results as we achieved several important milestones during the quarter. As shown on Slide 8 of this morning's deck, we reported a solid quarter of results across the board highlighted by strong growth in all the year-over-year profitability metrics. We reached a significant milestone by reporting positive adjusted EBITDA for the first time since the third quarter of 2018, which also represented the ninth consecutive quarter of improvement. This is an important achievement that reflects the progress we've made maximizing Flotek's revenue stream from our diversified business segments and our continued initiatives to drive cost improvements across the business. Lastly, we strengthened our liquidity with the entry into an ABL in August, which we were able to upsize in October. Looking at the income statement, Slide 9 shows the growth in total revenues over the last few years, including our latest guidance range for 2023. Third quarter revenues were 4% higher compared to the year ago quarter, but were down 6% compared to the second quarter of this year. As Ryan mentioned, the sequential decrease is attributable to the overall market pullback in upstream drilling and completion activity. On a positive note, Flotek's transactional chemistry revenues were up almost 80% from the first quarter of this year. In addition, using the midpoint of our latest revenue guidance, we would achieve annual revenue growth of 41% this year versus 2022, which certainly will be a tremendous achievement given the onshore market dynamics. As it relates to revenue, I'd like to briefly discuss Flotek's supply agreement with ProFrac. The agreement contains minimum requirements for annual chemistry purchases by ProFrac. If purchases do not meet the contractual requirements, we are entitled to additional payments at the conclusion of the measurement period, which currently runs from June 1, 2023 through December 31, 2023. Based on recent activities, we do not expect that the chemistry purchase requirements will be met during the measurement period. And accordingly, our third quarter and 9-month 2023 revenues include expected shortfall payments, which positively impacts our profitability. For more specifics regarding the supply agreement and the modifications and amendments that have been made to date, I encourage you to review the 8-Ks we filed on February 6 of this year and May 18, March 10 and February 4 of last year. Looking at Slide 10. Third quarter gross profit increased to $9 million compared to a gross loss of $2 million for the comparable period of 2022. Adjusted gross profit, which excludes certain noncash costs, totaled $10 million compared to gross profit of only $250,000 for the comparable quarter. Gross profit margin and a gross -- adjusted gross profit margin during the quarter increased to 19% and 22%, respectively. The improvement in third quarter gross profit was driven by the shortfall payments expected under the ProFrac supply agreement, an increase in our transactional chemistry revenue and continued cost reductions to material and freight. Adjusted gross profit through the first 9 months of 2023 is up $19 million versus the comparable period of 2022. Based on the midpoints of our updated guidance, we now anticipate an approximately $27 million improvement in full year 2023 adjusted gross profit compared to last year. Moving to Slide 11. Third quarter adjusted EBITDA was a positive $3.3 million. As shown on the chart, this is the ninth consecutive quarter of improvement in this metric. Touching on SG&A, third quarter totaled $6.5 million compared to $9.3 million for the third quarter of last year, a 30% year-over-year decline and improvement was primarily the result of lower employee compensation expense as well as reduced legal and professional fees. In October, we settled the final matter of previously disclosed litigation that began in 2021. The cost of this litigation has been nearly $2 million this year, so the resolution of this matter should be extremely beneficial as we begin to turn our focus to 2024 G&A costs. Going to the bottom line, we reported net income of $1.3 million in the third quarter compared to a net loss of $19 million in the comparable quarter of 2022. Net loss for the third quarter of last year did include a $4 million non-cash loss associated with the fair value change of our convertible notes. Touching on the balance sheet, in August, we announced the completion of an asset-based loan, which provided initial credit availability of $10 million. We were able to increase that to $13.8 million in October through the pledging of certain real estate assets. Approximately $5.4 million of borrowings are currently outstanding under the facility, which is subject to an 11% interest rate, and we currently have about $6.4 million of borrowings available under the ABL in addition to the roughly $3 million of cash currently on hand for total liquidity approaching $10 million. As it relates to our outlook on 4Q, we have updated our full year guidance as follows. As a result of the slowdown that Ryan touched upon earlier in onshore activity, total revenues are now expected to total $185 million to $200 million compared to a previous estimate of $210 million to $230 million. But really more importantly, adjusted gross profit margin has been increased to a range of 12% to 14%, which is up from the previous range of 8% to 10%. So if you take the midpoint of the new guidance, it would imply a 30% improvement in gross profit versus the previous guidance. That concludes my remarks. I'll now turn the call back over to Ryan for closing comments.